FDA Determines Regulatory Review Period for CELLCEPT Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for CELLCEPT, a human drug product, and is publishing this notice as required by law. The determination was made due to a patent extension application submitted to the Commissioner of Patents and Trademarks, Department of Commerce.